The problem is the Company has to be very careful
Post# of 148169
(Total Views: 526)
Posted On: 08/05/2020 11:33:58 AM
The problem is the Company has to be very careful not to cross the line between awareness and marketing. It would create frustration in the public if they tried to get prescribed leronlimab only to find out its not available. This would also create friction with the EFF-DA, which we've already seen NP treat with kid gloves out of what I perceive to be an abundance of caution.
BUT at some point we're gonna have to push back...no, fight back! Beauracracy is literally killing 100s of thousands.
BUT at some point we're gonna have to push back...no, fight back! Beauracracy is literally killing 100s of thousands.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼